Exchange transfusion in neonatal hyperbilirubinemia

Area of Science:

• Neonatal Medicine
• Pediatric Hematology
• Clinical Pediatrics

Background:

• Neonatal hyperbilirubinemia is a common condition requiring intervention.
• Exchange transfusion (ET) is a primary treatment for severe cases.
• Premature and low birth weight infants represent a higher-risk group.

Purpose of the Study:

• To analyze the indications, outcomes, and complications of exchange transfusion in term and preterm neonates.
• To identify the primary causes of hyperbilirubinemia necessitating ET.
• To evaluate mortality and morbidity associated with ET.

Main Methods:

• Retrospective analysis of 433 exchange transfusions in 225 term and 110 premature/low birth weight infants.
• Categorization of patients into term (Group I) and premature/low birth weight (Group II).
• Review of indications, complications, mortality, and delayed morbidities.

Main Results:

• Most infants required one ET (78.5%).
• Common causes included ABO hemolytic disease of the newborn (HDN), Rh HDN, septicemia, and G-6-PD deficiency, varying between term and preterm infants.
• Complications were higher in Group II (41.8%) vs. Group I (20.4%). Procedure-related mortality was 3.2/100 ET, decreasing to 0.9/100 ET when high-risk infants were excluded. Overall mortality was 10.6/100 ET.
• Leading causes of death were cardiorespiratory arrest, septicemia, and kernicterus. Delayed complications included anemia and clinical septicemia.

Conclusions:

• Exchange transfusion is effective but carries significant risks, particularly in premature infants.
• Septicemia and hemolytic disease of the newborn are major indications for ET.
• Reducing ET in high-risk neonates and prompt management of complications are crucial for improving survival rates.